Please ensure Javascript is enabled for purposes of website accessibility

POZEN Inc. Stock is Skyrocketing -- Here's Why

By Sean Williams - Jun 8, 2015 at 3:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

POZEN shares ascend to the heavens after it announces an acquisition. Normally the acquired company is the one that soars, but there's a big catch to this acquisition that POZEN shareholders are going to like.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of POZEN (NASDAQ: POZN), a pharmaceutical company focused on developing therapies to treat acute and chronic pain, lifted the pains of its shareholders away this morning by rising as much as 29% following the announcement of an overseas acquisition.

So what: Under normal circumstances the acquiring company is not often the one that soars, but there are substantial dollar-saving implications with POZEN's purchase.

According to the press release, which surprisingly came out while the market was open, POZEN announced the acquisition of Tribute Pharmaceutical Canada for what amounts to approximately $146 million. When the transaction is complete, which is expected in the fourth quarter of this year, the new company will be renamed Aralez Pharmaceuticals PLC.

However, what's truly material about this deal is that POZEN will relocate its headquarters overseas to Ireland, thus escaping the markedly higher than average marginal corporate tax rates in the United States. Known as a tax inversion deal, this buyout could save POZEN a substantial sum of money since Ireland's peak marginal tax rate for corporations is a mere 12.5% compared to as much as 40% in the United States.

Now what: While POZEN's management can spin the deal as bolstering their portfolio and international presence, the real allure are the tax savings -- even if they don't want to admit it. As you can tell by the reaction of the stock, the savings could be substantive and would make POZEN's current P/E of 12, even following today's monstrous run higher, look even more attractive.

It's possible POZEN could still offer additional upside to investors, but they should also keep in mind that POZEN's primary products are licensed-out and its drug development pipeline is far from a sure thing. For instance, POZEN has received two complete response letters concerning the manufacturing process for its low-dose aspiring combo of PA8140 and PA32540 last year alone. Beyond its licensed products, POZEN doesn't have much to be proud of in recent months.

For now I'd be comfortable monitoring from the sidelines, but would encourage investors to use its developing drugs as the catalyst of whether or not POZEN is worth buying.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.